Literature DB >> 16644076

Ensuring quality of in vitro alternative test methods: Current practice.

Amy Rispin1, Katherine Stitzel, John Harbell, Mitchell Klausner.   

Abstract

In Vitro toxicology methods are being validated and adopted by regulatory agencies for use as alternatives to animal testing. Such methods may use ex vivo tissues or bioconstructs, some of which may be proprietary. Users of the data from these methods need to be reassured that the assays or assay components used in their studies provide consistent, good quality data over time, matching the standards achieved during the validation process. This paper presents an overview of approaches currently used by representatives of a manufacturer and a contract testing laboratory to ensure that the results from in vitro alternative methods are reproducible and of high quality over time. These approaches include full characterization of cells or tissues, sampling of each lot of manufactured bioconstructs for performance, and regular use of controls and benchmark chemicals to provide assurance of consistency of assay performance.

Mesh:

Year:  2006        PMID: 16644076     DOI: 10.1016/j.yrtph.2005.03.005

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  3 in total

1.  An in vitro skin irritation test (SIT) using the EpiDerm reconstructed human epidermal (RHE) model.

Authors:  Helena Kandárová; Patrick Hayden; Mitchell Klausner; Joseph Kubilus; John Sheasgreen
Journal:  J Vis Exp       Date:  2009-07-13       Impact factor: 1.355

Review 2.  In vitro three-dimensional organotypic culture models of the oral mucosa.

Authors:  Mitchell Klausner; Yuki Handa; Seiya Aizawa
Journal:  In Vitro Cell Dev Biol Anim       Date:  2021-01-14       Impact factor: 2.416

3.  Effects of High-Temperature-Pressure Polymerized Resin-Infiltrated Ceramic Networks on Oral Stem Cells.

Authors:  Mathilde Tassin; Eric Bonte; Ludwig S Loison-Robert; Ali Nassif; Tsouria Berbar; Stéphane Le Goff; Ariane Berdal; Michael Sadoun; Benjamin P J Fournier
Journal:  PLoS One       Date:  2016-05-19       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.